SavedAdd your journal

Journals / Arşiv Kaynak Tarama Dergisi / 2016 / Cilt: 25 - Sayı: 3

Management of Medical Emergencies in Pediatric Oncology

Pediatrik Onkolojide Tıbbi Acillerin Yönetimi

Serhan KÜPELİ
Ahmet Çağrı ÇİFTÇİ
Pages
369–405
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although basic principles in management of pediatric oncologic emergencies are similar, some discrepancies can be seen in clinical applications in different institutions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pediatric oncologic emergencies are potentially life-threatening acute complications related to primary malignant disease or its treatment.
📊
Key Findings & Data:They can be divided in subgroups as metabolic emergencies, neurologic emergencies, thoracal emergencies, gastrointestinal emergencies, urogenital emergencies and febrile neutropenia.
💡
Conclusion & Impact:Although basic principles in management of pediatric oncologic emergencies are similar, some discrepancies can be seen in clinical applications in different institutions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Pediatric oncologic emergencies are potentially life-threatening acute complications related to primary malignant disease or its treatment. They can be divided in subgroups as metabolic emergencies, neurologic emergencies, thoracal emergencies, gastrointestinal emergencies, urogenital emergencies and febrile neutropenia. Pediatric oncologic emergencies can present with different signs and symptoms. Although basic principles in management of pediatric oncologic emergencies are similar, some discrepancies can be seen in clinical applications in different institutions.

Özet

Pediatrik onkolojik aciller primer hastalığa veya tedaviye bağlı olarak ortaya çıkan, potansiyel olarak hayatı tehdit eden akut komplikasyonlardır. Pediatrik onkolojik aciller metabolik aciller, nörolojik aciller, torakal aciller, gastrointestinal aciller, ürogenital aciller ve febril nötropeni olarak alt gruplara ayrılabilir. Pediatrik onkolojik aciller değişik semptom ve bulgularla kliniğe gelebilmektedir. Pediatrik onkolojik acillere yaklaşım ve tedavi konusunda temel ilkelerde benzerlik olsa da klinik uygulamalar kurumlar arasında oldukça farklılık gösterebilmektedir.

🔖

Cite This Article

KÜPELİ, S., ÇİFTÇİ, A. Ç. (2022). Management of Medical Emergencies in Pediatric Oncology. Arşiv Kaynak Tarama Dergisi, Cilt: 25 - Sayı: 3, 369–405. https://ajindex.com/articles/449302

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rheingold SR, Lange BJ. Oncologic emergencies. In Principles and Practice of Pediatric Oncology, 5th edition (Eds: AP Pizzo, DG Poplack):1202-30.
  2. Philadelphia, Lippincott, Williams&Wilkins, 2006.
  3. Celkan T, Gülen T. Tümör lizis sendromu; tanı, izlem ve tedavide yeni yaklaşımlar. Turk Pediatri Ars. 2013;48:188-94.
  4. Bose P, Qubaiah O. A review of Tumor lysis syndrome with targeted therapies and the role of rasburicase. J Clin Pharm Ther. 2011;36:299-326. Özkan A. Onkolojik aciller ve destek tedavi. In Pediatrik Onkoloji (Eds Ö Düzovalı, F Çorapcıoğlu, M Elli, A Dağdemir):1221-49. İstanbul: Nobel Tıp, 2009.
  5. Sandberg DI, Bilsky MH, Kushner BH, Souweidane MM, Kramer K, Laquaglia MP et al. Treatment of spinal involvement in neuroblastoma. Patients. Pediatr Neurosurg. 2003;39:291-8. Davilla ML. Neutropenic enterocolitis. Curr Opin Gastroenterol. 2006;22:44-7.
  6. Stillwell TJ, Benson RC. Cyclophosphamide-induced hemorrhagic cystitis, a review of 100 patients. Cancer. 1988;61:451-7. West NJ. Prevention and treatment of hemorrhagic cystitis. Pharmacotherapy. 1997;17:696-706.
  7. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51.
  8. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocyitosis, leukostasis and leukapheresis practice management. Blood Rev. 2012;26:117-22.
  9. Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A et al. Hyperleukocytic leukemias and leukostatis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39:1-18.
  10. StuckiA, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97:2121-9.
  11. Lowe EJ, Pui CH, Hancock ML, Geiger TL, Khan RB, Sandlund JT. Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer. 2005;45:10-5.
  12. Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. Leukocytoreduction for acute leukemia. Ther Apher. 2002;6:15-23.
  13. Nelson SC, Bruggers CS, Kurtzberg J, Friedman HS. Management of leukemic hyperleukocytosis with hydration, urinary alkalinization, and allopurinol: are cranial irradiation and invasive cytoreduction necessary? Am J Pediatr Hematol Oncol. 1993;15:351-5.
  14. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical c